SG11201702162PA - 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs - Google Patents

7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Info

Publication number
SG11201702162PA
SG11201702162PA SG11201702162PA SG11201702162PA SG11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA
Authority
SG
Singapore
Prior art keywords
piperazinyl
morpholinyl
anticancer drugs
pyridine derivatives
methyl thieno
Prior art date
Application number
SG11201702162PA
Inventor
Durga Prasad Konakanchi
Subba Rao Pula
Rama Krishna Pilli
Lakshmana Viswa Venkata Pavan Kumar Maddula
Srinivasa Krishna Murthy Konduri
Janaki Rama Rao Ravi
Naga Vasanta Srinivasu Vuppalapati
Sandeep Kumar Thoota
Pulla Reddy Muddasani
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of SG11201702162PA publication Critical patent/SG11201702162PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201702162PA 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs SG11201702162PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000770 WO2016092556A1 (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Publications (1)

Publication Number Publication Date
SG11201702162PA true SG11201702162PA (en) 2017-04-27

Family

ID=52595387

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702162PA SG11201702162PA (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Country Status (31)

Country Link
US (1) US10106554B2 (en)
EP (1) EP3230289B1 (en)
JP (1) JP6454419B2 (en)
KR (1) KR102328921B1 (en)
CN (1) CN107074873B (en)
AP (1) AP2017009749A0 (en)
AU (1) AU2014413483B2 (en)
BR (1) BR112017005518B1 (en)
CA (1) CA2959980C (en)
CO (1) CO2017002266A2 (en)
CY (1) CY1122080T1 (en)
DK (1) DK3230289T3 (en)
EA (1) EA036819B1 (en)
ES (1) ES2750268T3 (en)
HR (1) HRP20192041T1 (en)
HU (1) HUE047144T2 (en)
IL (1) IL252254B (en)
LT (1) LT3230289T (en)
MA (1) MA40110B2 (en)
MX (1) MX2017004782A (en)
MY (1) MY188946A (en)
NZ (1) NZ729078A (en)
PH (1) PH12017500342A1 (en)
PL (1) PL3230289T3 (en)
PT (1) PT3230289T (en)
RS (1) RS59409B1 (en)
SG (1) SG11201702162PA (en)
SI (1) SI3230289T1 (en)
UA (1) UA117318C2 (en)
WO (1) WO2016092556A1 (en)
ZA (1) ZA201701036B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221905A1 (en) * 2019-10-11 2022-12-23 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2
US20230046892A1 (en) 2019-12-20 2023-02-16 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
EP4326276A1 (en) * 2021-04-21 2024-02-28 Natco Pharma Ltd Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579526A (en) 1968-11-13 1971-05-18 Research Corp Preparation of thienopyridines
FR2411838A1 (en) 1977-12-19 1979-07-13 Parcor NEW DERIVATIVES OF THIENO (2-3-C) AND (3,2-C) PYRIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab Kinase inhibitors as therapeutic agents
EP2032582A1 (en) * 2006-04-26 2009-03-11 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
TWI471134B (en) 2007-09-12 2015-02-01 Genentech Inc Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
CL2009000780A1 (en) 2008-03-31 2010-01-15 Genentech Inc Substituted heterocyclyl-pyran-heterocyclyl, heterocyclyl-oxepine-heterocyclyl, benzopyran-heterocyclyl and substituted benzoxepine-heterocyclyl derived compounds; pharmaceutical composition; process for preparing the composition; pharmaceutical kit; and its use in the treatment of cancer, mediated by the inhibition of pi3k.
SI2385832T1 (en) * 2009-01-08 2015-10-30 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CA2775942A1 (en) * 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
BR112013020329A2 (en) * 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors

Also Published As

Publication number Publication date
PL3230289T3 (en) 2020-03-31
KR20170090434A (en) 2017-08-07
LT3230289T (en) 2019-10-10
IL252254B (en) 2019-08-29
EP3230289A1 (en) 2017-10-18
CN107074873B (en) 2022-01-07
US10106554B2 (en) 2018-10-23
US20170320891A1 (en) 2017-11-09
CN107074873A (en) 2017-08-18
DK3230289T3 (en) 2019-10-28
EA201791294A1 (en) 2017-11-30
JP6454419B2 (en) 2019-01-16
AP2017009749A0 (en) 2017-02-28
MX2017004782A (en) 2017-07-27
HUE047144T2 (en) 2020-04-28
CA2959980C (en) 2023-04-25
ES2750268T3 (en) 2020-03-25
WO2016092556A1 (en) 2016-06-16
IL252254A0 (en) 2017-07-31
JP2017537139A (en) 2017-12-14
MA40110A1 (en) 2017-12-29
PT3230289T (en) 2019-10-30
BR112017005518B1 (en) 2022-11-29
BR112017005518A2 (en) 2017-12-05
HRP20192041T1 (en) 2020-02-07
AU2014413483A1 (en) 2017-03-09
EP3230289B1 (en) 2019-08-14
AU2014413483B2 (en) 2019-07-25
ZA201701036B (en) 2019-06-26
MY188946A (en) 2022-01-14
CY1122080T1 (en) 2020-11-25
NZ729078A (en) 2021-07-30
PH12017500342A1 (en) 2017-07-17
UA117318C2 (en) 2018-07-10
EA036819B1 (en) 2020-12-23
SI3230289T1 (en) 2019-10-30
KR102328921B1 (en) 2021-11-19
MA40110B2 (en) 2020-12-31
CO2017002266A2 (en) 2017-05-31
CA2959980A1 (en) 2016-06-16
RS59409B1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
HK1244804A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL252065B (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
IL251441B (en) Imidazo pyridine derivatives and pharmaceutical compositions containing them
HK1231416A1 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IL251780B (en) 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-1hpyrrolo[2,3-c]pyridine derivatives and pharmaceutical compositions comprising them
IL252254A0 (en) 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
IL251067B (en) 4-(phenyl/heteroaryl)-7-(phenyl/pyrid-4-yl)-5,8-dihydro-5,8-ethanopyrido[3,4-d]pyrimidine derivatives and pharmaceutical compositions comprising them
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
IL250267A0 (en) Indolizine derivatives, their preparation and pharmaceutical compositions containing them
IL252578B (en) Derivatives of 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one and pharmaceutical compositions comprising them
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
IL252579B (en) Derivatives of methyl-(1h-pyrazol-4-yl)-3-methyl-1h-pyrazolo[4,3-d]pyrimidine and pharmaceutical compositions comprising them
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL243739A0 (en) Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders
EP3150584A4 (en) 3,4-dihydroquinazoline derivative and complex preparation containing same
HUE038944T2 (en) Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors
GEP20197016B (en) 7-(morpholinyl)-2-(n-piperazinyl)methyl thieno[2,3-c]pyridine derivatives as anticancer drugs
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS